United Kingdom | English

Clinical Evidence

Dexcom is committed to providing healthcare professionals with the latest clinical evidence to demonstrate positive outcomes for Dexcom CGM. We’ve also included available professional society guidance and criteria that can help identify patients who could benefit from CGM technology.

Clinical Studies

Review Peer-reviewed evidence demonstrating the positive impact that CGM has on glycaemic control and variability.

Dexcom CGM Benefits for MDI patients: The COMISAIR Study
Persistent Use of Dexcom CGM in MDI patients: The DIaMonD Study
Improved Glycaemic Control in MDI patients: The DIaMonD Study
Improvement in Quality of Life (QoL) with Dexcom CGM: The GOLD Study
Significant Reduction in Hypo Events in High-Risk MDI patients: The HypoDE Study
Dexcom CGM Outperforms Abbott Freestyle Libre: I HART CGM Study
Improved glucose management in youths with T1D: The CITY study
Reduction of hypoglycaemia in older adults: The WISDM study
Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes
Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction by CGM in People With Type 1 Diabetes Treated With MDI: The SILVER Study
The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: Further findings from the DIAMOND randomized clinical trial
Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the Landmark study
Lower HbA1c with real-time Continuous Glucose Monitoring (rtCGM) than with intermittently scanned Continuous Glucose Monitoring (isCGM) after 1 year: the CORRIDA LIFE study
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Use of intermittently scanned continuous glucose monitoring in young people with high-risk type 1 diabetes-Extension phase outcomes following a 6-month randomized control trial
Marked Improvement in A1C Levels After Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Maintained Over 4 Years in Patients With Type 1 Diabetes
Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial
Real-world hypoglycemia avoidance with a continuous glucose monitoring system’s predictive low glucose alert
Real-World Hypoglycemia Avoidance With a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views
Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alert
Real-world glycaemic outcomes in adult persons with type 1 diabetes using a real-time continuous glucose monitor compared to an intermittently scanned glucose monitor
A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia

Professional Society Guidelines

Professional societies continue to expand their recommendation of continuous glucose monitoring (CGM) use in patient care protocols for both adult and paediatric patients with type 1 diabetes. Based on the NHS funding criteria, it is estimated that up to 70% of patients with T1D may be eligible for Dexcom G6.(1)

NICE Adult Guidance NG17
NICE Children & Young People Guidance NG18
NICE Pregnancy Guidance NG3 Pregnancy
Diabetes UK. Type 1 Diabetes Technology: A Consensus Guideline
The Scottish Health Technology Group (SHTG) recommendation for Continuous glucose monitoring in pregnant women with type 1 diabetes
HEALTH TECHNOLOGY WALES GUIDANCE 012 - PREGNANCY

(1) NHS Digital. National Diabetes Insulin Pump Audit (2017-18), 08 August 2019